H
Humacyte
Global leader in engineering regenerative medicine products to save and improve patient lives
About Humacyte
Humacyte, Inc. is a biotechnology startup based in Durham, North Carolina, that specializes in the development and manufacture of bioengineered human tissues and organs. These products are designed to be universally implantable, aiming to revolutionize medical treatments and improve patient lives. The company's flagship product is the Humacyte Human Acellular Vessel (HAV), a regenerative vascular conduit. This product is currently undergoing various stages of clinical trials for multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.
Humacyte's business model revolves around the development of these bioengineered products, which are then sold to healthcare providers. The company operates in the biotechnology and healthcare markets, serving clients such as hospitals, clinics, and other medical facilities. Its revenue is generated through the sale of these bioengineered tissues and organs.
The company also believes its platform technology has the potential to create solutions for complex organ diseases. This includes the development of bioengineered replacement tissues and organs for procedures such as coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes.
Founded in 2004 by Dr. Laura Niklason, a world leader in tissue engineering, along with Drs. Juliana Blum and Shannon Dahl, Humacyte is listed on the Nasdaq under the ticker symbol HUMA.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- Public via SPAC 2021
Open roles
Humacyte in the Durham ecosystem
The Humacyte office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A6 investors entered at this stage
Bangkok Bank
Reignwood Group
Brady Dougan
Access Industries
Pacific Eagle Asset Management
Gavril Yushvaev
Series B and later8 investors entered at this stage
- CCCarrie Cox
California Institute Of Medical Science
Fresenius Medical Care
Alpha Healthcare Acquisition Corp
Standard Treasury
Silicon Valley Bank
Oberland Capital
Avenue Capital Group
Source: Dealroom Talent Intelligence.
Patents
20 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Humacyte on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Humacyte's bioengineered vessel outperforms fistulas in Lancet Digital Health dialysis-access data
Humacyte wins FDA IND clearance for first-in-human CTEV study in coronary artery bypass grafting
